Recent Publications

• 1. Ryan Wolf J
  2. Chen A
  3. Wieser J
  4. Johnson B
  5. Baughman L
  6. Lee G
  7. Pope E
  8. Franco A
  9. Love T
  10. Beck LA
  Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2024 Feb 15.
• 1. Stolarczyk A
  2. Perez-Nazario N
  3. Knowlden SA
  4. Chinchilli E
  5. Grier A
  6. Paller A
  7. Gill SR
  8. De Benedetto A
  9. Yoshida T
  10. Beck LA
  Bleach baths enhance skin barrier, reduce itch but do not normalize skin dysbiosis in atopic dermatitis.; Archives of dermatological research. 2023 Sep 27.
• 1. Moran MC
  2. Brewer MG
  3. Schlievert PM
  4. Beck LA
  S. aureus virulence factors decrease epithelial barrier function and increase susceptibility to viral infection.; Microbiology spectrum. 2023 Sep 22.
• 1. Moran MC
  2. Klose A
  3. Yoshida T
  4. De Benedetto A
  5. Schneider LC
  6. Ong PY
  7. Simpson EL
  8. Leung DYM
  9. Miller BL
  10. Seplaki CL
  11. Beck LA
  History of S. aureus Skin Infection Significantly Associates with History of Eczema Herpeticum in Patients with Atopic Dermatitis.; Dermatology and therapy. 2023 Aug 24.
• 1. Guttman-Yassky E
  2. Silverberg JI
  3. Thaçi D
  4. Papp KA
  5. Ständer S
  6. Beck LA
  7. Kim BS
  8. Hu X
  9. Liu J
  10. Calimlim BM
  11. Vigna N
  12. Crowley JT
  13. Teixeira HD
  14. Thyssen JP
  Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2023 Aug 01.
• 1. Reich K
  2. Silverberg JI
  3. Papp KA
  4. Deleuran M
  5. Katoh N
  6. Strober B
  7. Beck LA
  8. de Bruin-Weller M
  9. Werfel T
  10. Zhang F
  11. Biswas P
  12. DiBonaventura MD
  13. Chan G
  14. Johnson S
  15. Farooqui SA
  16. Kerkmann U
  17. Clibborn C
  Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2023 Jun 19.
• 1. Reich K
  2. Silverberg JI
  3. Papp KA
  4. Deleuran M
  5. Katoh N
  6. Strober B
  7. Beck LA
  8. de Bruin-Weller M
  9. Werfel T
  10. Zhang F
  11. Biswas P
  12. DiBonaventura MD
  13. Chan G
  14. Farooqui SA
  15. Kerkmann U
  16. Clibborn C
  Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2023 Jun 15.
• 1. Simpson EL
  2. Schlievert PM
  3. Yoshida T
  4. Lussier S
  5. Boguniewicz M
  6. Hata T
  7. Fuxench Z
  8. De Benedetto A
  9. Ong PY
  10. Ko J
  11. Calatroni A
  12. Rudman Spergel AK
  13. Plaut M
  14. Quataert SA
  15. Kilgore SH
  16. Peterson L
  17. Gill AL
  18. David G
  19. Mosmann T
  20. Gill SR
  21. Leung DYM
  22. Beck LA
  Rapid Reduction in Staphylococcus aureus in Atopic Dermatitis Subjects Following Dupilumab Treatment.; The Journal of allergy and clinical immunology. 2023 Jun 12.
• 1. Guttman-Yassky E
  2. Bahadori L
  3. Brooks L
  4. Clark KL
  5. Grindebacke H
  6. Ho CN
  7. Katial R
  8. Pham TH
  9. Walton C
  10. Datto CJ
  Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.; Journal of the European Academy of Dermatology and Venereology : JEADV; Vol 37(10), pp. e1211-e1214. 2023 Jun 12.
• 1. Arnold KA
  2. Peterson LF
  3. Beck LA
  4. Brewer MG
  JAK Signaling Is Critically Important in Cytokine-Induced Viral Susceptibility of Keratinocytes.; International journal of molecular sciences; Vol 24(11). 2023 May 25.
• 1. Simpson EL
  2. De Benedetto A
  3. Boguniewicz M
  4. Ong PY
  5. Lussier S
  6. Villarreal M
  7. Schneider LC
  8. Paller AS
  9. Guttman-Yassky E
  10. Hanifin JM
  11. Spergel JM
  12. Barnes KC
  13. David G
  14. Austin B
  15. Leung DYM
  16. Beck LA
  Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity from the ADRN Registry.; The journal of allergy and clinical immunology. In practice. 2023 May 12.
• 1. Moran MC
  2. Chinchilli E
  3. Kenney HM
  4. Pope EM
  5. Scott G
  6. Brewer MG
  7. Beck LA
  Stage of Keratinocyte Differentiation is a Key Determinant of Viral Susceptibility in Human Skin.; The Journal of investigative dermatology. 2023 Mar 28.
• 1. Zuberbier T
  2. Beck LA
  3. Bedbrook A
  4. de Bruin-Weller M
  5. Bousquet J
  6. Cork M
  7. Douladiris N
  8. Katoh N
  9. Mortz CG
  10. Werfel T
  11. Wojciech F
  12. Wollenberg A
  13. Siemens K
  14. Stevanovic K
  15. Worm M
  Developing integrated care pathways for atopic dermatitis-Challenges and unmet needs.; Clinical and translational allergy; Vol 13(3), pp. e12236. 2023 Mar.
• 1. Smith HD
  2. Williams B
  3. Beck LA
  4. De Benedetto A
  Erythema Multiforme Secondary to Poison Ivy Contact Dermatitis.; Dermatitis : contact, atopic, occupational, drug. 2023 Feb 27.
• 1. Yang B
  2. Wilkie H
  3. Das M
  4. Timilshina M
  5. Bainter W
  6. Woods B
  7. Daya M
  8. Boorgula MP
  9. Mathias RA
  10. Lai P
  11. Petty CR
  12. Weller E
  13. Harb H
  14. Leung DYM
  15. Beck LA
  16. Simpson EL
  17. Hata TR
  18. Barnes KC
  19. Phipatanakul W
  20. Leyva-Castillo JM
  21. Geha RS
  The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in mice.; The Journal of allergy and clinical immunology. 2023 Jan 20.
• 1. Bissonnette R
  2. Simpson E
  3. Eichenfield LF
  4. Guttman-Yassky E
  5. Silverberg JI
  6. Beck LA
  7. Mija L
  8. Thyssen JP
  9. Bieber T
  10. Kabashima K
  11. Siegfried E
  12. Stingl G
  13. van de Kerkhof P
  14. Yosipovitch G
  15. Paul C
  16. Paller AS
  The vIGA-AD scale for atopic dermatitis: uptake in the past five years and position of the International Eczema Council.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2023 Jan 09.
• 1. Schlievert PM
  2. Kilgore SH
  3. Beck LA
  4. Yoshida T
  5. Klingelhutz AJ
  6. Leung DYM
  Host Cationic Antimicrobial Molecules Inhibit S. aureus Exotoxin Production.; mSphere. 2023 Jan 04.
• 1. Moran MC
  2. Pope EM
  3. Brewer MG
  4. Beck LA
  Supply Chain Disruptions During COVID Pandemic Uncover Differences in Keratinocyte Culture Media.; JID innovations : skin science from molecules to population health. 2022 Aug 22.
• 1. Paller AS
  2. Beck LA
  Bleach baths for atopic dermatitis: Evidence of efficacy but more data are needed.; Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology; Vol 128(6). 2022 Jun.
• 1. Beck LA
  2. Deleuran M
  3. Bissonnette R
  4. de Bruin-Weller M
  5. Galus R
  6. Nakahara T
  7. Seo SJ
  8. Khokhar FA
  9. Vakil J
  10. Xiao J
  11. Marco AR
  12. Levit NA
  13. O'Malley JT
  14. Shabbir A
  Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.; American journal of clinical dermatology. 2022 May 03.
• 1. Beck LA
  2. Cork MJ
  3. Amagai M
  4. De Benedetto A
  5. Kabashima K
  6. Hamilton JD
  7. Rossi AB
  Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.; JID innovations : skin science from molecules to population health; Vol 2(5), pp. 100131. 2022 Apr 26.
• 1. Brewer MG
  2. Monticelli SR
  3. Moran MC
  4. Miller BL
  5. Beck LA
  6. Ward BM
  Conditions That Simulate the Environment of Atopic Dermatitis Enhance Susceptibility of Human Keratinocytes to Vaccinia Virus.; Cells; Vol 11(8). 2022 Apr 14.
• 1. Pope EM
  2. Laageide L
  3. Beck LA
  Management of Allergic Skin Disorders in Pregnancy.; Immunology and allergy clinics of North America; Vol 43(1), pp. 117-132. 2022 Jan 28.
• 1. Paller AS
  2. Beck LA
  3. Blauvelt A
  4. Siegfried EC
  5. Cork MJ
  6. Wollenberg A
  7. Chen Z
  8. Khokhar FA
  9. Vakil J
  10. Zhang A
  11. Bansal A
  12. Cyr SL
  Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.; Pediatric dermatology. 2022 Jan 26.
• 1. Beck LA
  2. Pesonen M
  3. Thakar J
  4. Georas SN
  5. Järvinen KM
  IgE Sensitization Drives the Atopic March.; American journal of respiratory and critical care medicine. 2022 Jan 08.
• 1. Beck LA
  2. Bieber T
  3. Weidinger S
  4. Tauber M
  5. Saeki H
  6. Irvine AD
  7. Eichenfield LF
  8. Werfel T
  9. Arlert P
  10. Jiang L
  11. Røpke M
  12. Paller AS
  Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.; Journal of the American Academy of Dermatology. 2022 Jan 03.
• 1. Herman KE
  2. Yoshida T
  3. Hughson A
  4. Grier A
  5. Gill SR
  6. Beck LA
  7. Fowell DJ
  IL-17-Dependent Dysregulated Cutaneous Immune Homeostasis in the Absence of the Wiskott-Aldrich Syndrome Protein.; Frontiers in immunology; Vol 13. 2022.
• 1. Yoshida T
  2. Beck LA
  3. De Benedetto A
  Skin barrier defects in atopic dermatitis: From old idea to new opportunity.; Allergology international : official journal of the Japanese Society of Allergology. 2021 Dec 13.
• 1. Tuttle KL
  2. Forman J
  3. Beck LA
  Novel systemic treatments in atopic dermatitis: Are there sex differences?; International journal of women's dermatology; Vol 7(5Part A). 2021 Dec.
• 1. Wollenberg A
  2. Beck LA
  3. de Bruin Weller M
  4. Simpson EL
  5. Imafuku S
  6. Boguniewicz M
  7. Zachariae R
  8. Olsen CK
  9. Thyssen JP
  Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.; The British journal of dermatology. 2021 Oct 12.
• 1. Daya M
  2. Cox C
  3. Acevedo N
  4. Boorgula MP
  5. Campbell M
  6. Chavan S
  7. Cho MH
  8. David GL
  9. Kachroo P
  10. Lasky-Su J
  11. Li X
  12. McHugh CP
  13. Qiao D
  14. Rafaels N
  15. Beck LA
  16. Bleecker ER
  17. Caraballo L
  18. Cupples AL
  19. Figueiredo CA
  20. Gallo RL
  21. Hanifin J
  22. Hansel NN
  23. Hata TR
  24. Hersh CP
  25. Knight-Madden J
  26. Leung DYM
  27. Guttman-Yassky E
  28. Meyers DA
  29. O'Connor G
  30. Ober C
  31. Ong PY
  32. Ortega VE
  33. Paller AS
  34. Putcha N
  35. Reed RM
  36. Schneider LC
  37. Silverman EK
  38. Slifka MK
  39. Spergel JM
  40. Vasan RS
  41. Viaud-Martinez KA
  42. Watson H
  43. Weiss ST
  44. Ruczinski I
  45. Beaty TH
  46. Mathias RA
  47. Barnes KC
  Multi-ethnic genome-wide and HLA association study of total serum IgE.; The Journal of allergy and clinical immunology. 2021 Sep 15.
• 1. Arehart CH
  2. Daya M
  3. Campbell M
  4. Boorgula MP
  5. Rafaels N
  6. Chavan S
  7. David G
  8. Hanifin J
  9. Slifka MK
  10. Gallo RL
  11. Hata T
  12. Schneider LC
  13. Paller AS
  14. Ong PY
  15. Spergel JM
  16. Guttman-Yassky E
  17. Leung DYM
  18. Beck LA
  19. Gignoux CR
  20. Mathias RA
  21. Barnes KC
  Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors.; The Journal of allergy and clinical immunology. 2021 Jun 07.
• 1. Moran MC
  2. Pandya RP
  3. Leffler KA
  4. Yoshida T
  5. Beck LA
  6. Brewer MG
  Characterization of Human Keratinocyte Cell Lines for Barrier Studies.; JID innovations; Vol 1(2). 2021 Jun.
• 1. Siegfried EC
  2. Bieber T
  3. Simpson EL
  4. Paller AS
  5. Beck LA
  6. Boguniewicz M
  7. Schneider LC
  8. Khokhar FA
  9. Chen Z
  10. Prescilla R
  11. Mina-Osorio P
  12. Bansal A
  Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.; American journal of clinical dermatology. 2021 Mar 03.
• 1. Mahadevan N
  2. Christakis Y
  3. Di J
  4. Bruno J
  5. Zhang Y
  6. Dorsey ER
  7. Pigeon WR
  8. Beck LA
  9. Thomas K
  10. Liu Y
  11. Wicker M
  12. Brooks C
  13. Kabiri NS
  14. Bhangu J
  15. Northcott C
  16. Patel S
  Development of digital measures for nighttime scratch and sleep using wrist-worn wearable devices.; NPJ digital medicine; Vol 4(1). 2021 Mar 03.
• 1. Beck LA
  2. Thaçi D
  3. Deleuran M
  4. de Bruin-Weller M
  5. Chen Z
  6. Khokhar FA
  7. Zhang M
  8. Ozturk ZE
  9. Shumel B
  Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.; The Journal of dermatological treatment. 2021 Feb 08.
• 1. Bin L
  2. Malley C
  3. Taylor P
  4. PreethiBoorgula M
  5. Chavan S
  6. Daya M
  7. Mathias M
  8. Shankar G
  9. Rafaels N
  10. Vergara C
  11. Potee J
  12. Campbell M
  13. Hanifin JM
  14. Simpson E
  15. Schneider LC
  16. Gallo RL
  17. Hata T
  18. Paller AS
  19. De Benedetto A
  20. Beck LA
  21. Ong PY
  22. Guttman-Yassky E
  23. Richers B
  24. Baraghoshi D
  25. Ruczinski I
  26. Barnes K
  27. Leung DYM
  28. Mathias RA
  Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum.; Allergy. 2021 Feb 06.
• 1. Boguniewicz M
  2. Beck LA
  3. Sher L
  4. Guttman-Yassky E
  5. Thaçi D
  6. Blauvelt A
  7. Worm M
  8. Corren J
  9. Soong W
  10. Lio P
  11. Rossi AB
  12. Lu Y
  13. Chao J
  14. Eckert L
  15. Gadkari A
  16. Hultsch T
  17. Ruddy M
  18. Mannent LP
  19. Graham NMH
  20. Pirozzi G
  21. Chen Z
  22. Ardeleanu M
  Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis.; The journal of allergy and clinical immunology. In practice. 2021 Jan 13.
• 1. Bawany F
  2. Northcott CA
  3. Beck LA
  4. Pigeon WR
  Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies.; The journal of allergy and clinical immunology. In practice. 2020 Dec 12.
• 1. Bawany F
  2. Franco AI
  3. Beck LA
  Dupilumab: One therapy to treat multiple atopic diseases.; JAAD case reports; Vol 6(11). 2020 Nov.
• 1. Beck LA
  2. Silverberg JI
  3. Simpson EL
  4. Yosipovitch G
  5. Eckert L
  6. Guillemin I
  7. Chen Z
  8. Ardeleanu M
  9. Plaum S
  10. Graham N
  11. Ruddy M
  12. Pirozzi G
  13. Gadkari A
  Dupilumab Significantly Improves Sleep Outcomes in Adult Patients with Atopic Dermatitis: Results from Five Randomized Clinical Trials.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2020 Aug 12.
• 1. Paller AS
  2. Siegfried EC
  3. Thaçi D
  4. Wollenberg A
  5. Cork MJ
  6. Arkwright PD
  7. Gooderham M
  8. Beck LA
  9. Boguniewicz M
  10. Sher L
  11. Weisman J
  12. O'Malley JT
  13. Patel N
  14. Hardin M
  15. Graham NMH
  16. Ruddy M
  17. Sun X
  18. Davis JD
  19. Kamal MA
  20. Khokhar FA
  21. Weinreich DM
  22. Yancopoulos GD
  23. Beazley B
  24. Bansal A
  25. Shumel B
  Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial.; Journal of the American Academy of Dermatology. 2020 Jun 20.
• 1. Beck LA
  2. Thaçi D
  3. Deleuran M
  4. Blauvelt A
  5. Bissonnette R
  6. de Bruin-Weller M
  7. Hide M
  8. Sher L
  9. Hussain I
  10. Chen Z
  11. Khokhar FA
  12. Beazley B
  13. Ruddy M
  14. Patel N
  15. Graham NMH
  16. Ardeleanu M
  17. Shumel B
  Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.; American journal of clinical dermatology. 2020 Jun 17.
• 1. Wollenberg A
  2. Beck LA
  3. Blauvelt A
  4. Simpson EL
  5. Chen Z
  6. Chen Q
  7. Shumel B
  8. Khokhar FA
  9. Hultsch T
  10. Rizova E
  11. Rossi AB
  12. Graham NMH
  13. Pirozzi G
  14. Lu Y
  15. Ardeleanu M
  Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.; The British journal of dermatology; Vol 182(6). 2020 Jun.
• 1. Moran MC
  2. Beck LA
  3. Richardson CT
  A Spectrum of Skin Disease: How Staphylococcus aureus Colonization, Barrier Dysfunction, and Cytokines Shape the Skin.; The Journal of investigative dermatology; Vol 140(5). 2020 May.
• 1. Simpson E
  2. Bissonnette R
  3. Eichenfield LF
  4. Guttman E
  5. King B
  6. Silverberg JI
  7. Beck LA
  8. Bieber T
  9. Reich K
  10. Kabashima K
  11. Seyger M
  12. Siegfried E
  13. Stingl G
  14. Feldman SR
  15. Menter A
  16. van de Kerkhof P
  17. Yosipovitch G
  18. Paul C
  19. Martel P
  20. Dubost-Brama A
  21. Armstrong J
  22. Chavda R
  23. Frey S
  24. Joubert Y
  25. Milutinovic M
  26. Parneix A
  27. Teixeira HD
  28. Lin CY
  29. Sun L
  30. Klekotka P
  31. Nickoloff B
  32. Dutronc Y
  33. Mallbris L
  34. Janes JM
  35. DeLozier AM
  36. Nunes F
  37. Paller AS
  The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.; Journal of the American Academy of Dermatology. 2020 Apr 25.
• 1. Wieser JK
  2. Kuehn GJ
  3. Prezzano JC
  4. Cusick EH
  5. Stiegler JD
  6. Scott GA
  7. Liesveld JL
  8. Beck LA
  Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment.; JAAD case reports; Vol 6(4). 2020 Apr.
• 1. Platts-Mills TAE
  2. Commins SP
  3. Biedermann T
  4. van Hage M
  5. Levin M
  6. Beck LA
  7. Diuk-Wasser M
  8. Jappe U
  9. Apostolovic D
  10. Minnicozzi M
  11. Plaut M
  12. Wilson JM
  On the cause and consequences of IgE to galactose-α-1,3-galactose: A report from the National Institute of Allergy and Infectious Diseases Workshop on Understanding IgE-Mediated Mammalian Meat Allergy.; The Journal of allergy and clinical immunology; Vol 145(4). 2020 Apr.
• 1. Bawany F
  2. Beck LA
  3. Järvinen KM
  Halting the March: Primary Prevention of Atopic Dermatitis and Food Allergies.; The journal of allergy and clinical immunology. In practice; Vol 8(3). 2020 Mar.
• 1. Guttman-Yassky E
  2. Thaçi D
  3. Pangan AL
  4. Hong HC
  5. Papp KA
  6. Reich K
  7. Beck LA
  8. Mohamed MF
  9. Othman AA
  10. Anderson JK
  11. Gu Y
  12. Teixeira HD
  13. Silverberg JI
  Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.; The Journal of allergy and clinical immunology; Vol 145(3). 2020 Mar.